Agency Says Tests You Are Using to Diagnose Breast Cancer Are the “Evaluation Tool of

Agency Says Tests You Are Using to Diagnose Breast Cancer Are the “Evaluation Tool of Choice” for Public

Undeclared Version of 2.5% Health Mistake’s Video Titled ‘What You Should Know About Estrogen-Induced Breast Cancer’

Scientists in Bethesda, Maryland, have discovered a video of the maker of two C.D.C. Breast Cancer Screening Tests aired on HGTV’s “The Junk Food Diaries” as they were produced. The maker’s video included a mix of facts and highly damaging hype, including the statement that the “2.5% of their videos are geared toward those high risk in terms of a close relative, breast cancer”.

The video title was, simply, “What You Should Know About Estrogen-Induced Breast Cancer (E.I.B.C.)”. The video listed other studies from around the world that showed women with a close relative diagnosed with breast cancer before age 60 were 30% more likely to develop E.I.B.C., however, none of the studies showed this figure being as high as 40%.

The video also stated that while these breast cancer warning signs were recognized worldwide, that has not come to pass for women in the US.

The C.D.C. provided evidence to Congress to prove the video was released in 2012 when the US government found an existing fault with the testing they were selling at the time. The test utilized now discarded gene mutations for E.I.B.C. And while this raised the same risk to 40%, test kits do not post the results on a web interface like other tests used to screen for E.I.B.C.

The video mentioned that 85% of all men and 95% of all women now had the disease but the company’s kits didn’t highlight this risk. The only way to access the test’s results was to request a white paper sent in the mail. While this was a greater convenience than the test could not accept such a small request.

However, the C.D.C. of course believes consumers should have the right to create their own information for themselves about E.I.B.C. and recommended funding clinical trials in 3 different countries in order to find a proof of benefit of E.I.B.C..

As the government noted, the manufacturer’s video is just one in a batch of thirteen that have been released around the world. And this creates a confusing path for a cancer patient who can consult five doctors without knowing which brand E.I.B.C. does not fit in. When looking for information on the same type of test, standard disclaimers are recommended.

If you have questions, consider consulting your doctor.

Contributor image.

For a description of how the breast cancer screening test is being classified as a global vector cancer for active cancer treatment, please visit:

Get these, as well as all the National Cancer Institute publications at this URL:

Article Description: Breast cancer screening test: Overstated by the manufacturer, a “genetic potential modifier” should be replaced. A misspelling of the company’s name, and a typo have created confusion among the public. Moreover, the public has the opportunity to effectively communicate their concern to the company.

About the Author: Shishir Shinde is Assistant Professor of Biology and Public Health and the Research Director of the Public Health Genetics Laboratory at Duke University Medical Center in Durham, North Carolina. His research interests include genomic foundations for disease, genetic databases, biomarkers of disease and environmental exposures. He is co-author of numerous papers in peer-reviewed journals on the links between exposure to dangerous chemicals and biological pathways leading to cancers, as well as a fellow of the International Society for Systems Biology, the Personal Genome Project, the American Cancer Society, the American Association for Cancer Research, The Boston Society of Gastroenterology, and the International Journal of Cancer Research. He has researched this issue in regions ranging from California to Mexico to Japan. Dr. Shinde holds several U.S. and Japanese patents, developed a software algorithm for selecting the most active genetic bases, and has advocated that clinical trials and diagnostic tests should accurately and reliably inform the population about their risk of developing cancer, as well as be selective of potential carcinogens. Dr. Shinde is a member of the American Association for Cancer Research. For more, visit Shishir Shinde is Assistant Professor of Biology and Public Health and the Research Director of the Public Health Genetics

Leave a Comment